← Back to Search

Other

Cocktail Probe Substrates + BMS-986419 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug, BMS-986419, to see how it affects the body's handling of other common medications in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cocktail Probe Substrates + BMS-986419Experimental Treatment7 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Caffeine
2014
Completed Phase 3
~2980
Bupropion
2011
Completed Phase 4
~3310
Midazolam
2018
Completed Phase 4
~1910
Flurbiprofen
2022
Completed Phase 4
~870
BMS-986419
2023
Completed Phase 1
~30
Omeprazole
2006
Completed Phase 4
~940
Fexofenadine
2016
Completed Phase 4
~950

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,682 Previous Clinical Trials
4,129,547 Total Patients Enrolled

Media Library

BMS-986419 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05932277 — Phase 1
Healthy Subjects Research Study Groups: Cocktail Probe Substrates + BMS-986419
Healthy Subjects Clinical Trial 2023: BMS-986419 Highlights & Side Effects. Trial Name: NCT05932277 — Phase 1
BMS-986419 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05932277 — Phase 1
~9 spots leftby Nov 2025